{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:31:37Z","timestamp":1770816697181,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.revmed.2019.09.003","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T09:15:52Z","timestamp":1572254152000},"page":"489-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["N\u00e9crose h\u00e9morragique bilat\u00e9rale des surr\u00e9nales sous apixaban\u00a0: penser au syndrome des antiphospholipides\u00a0?"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8904-7080","authenticated-orcid":false,"given":"V.","family":"Lavoipierre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Soubrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"De Sainte Marie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Seux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Solas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Morange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bernit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ebbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Faucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Harl\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Schleinitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.revmed.2019.09.003_bib0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.rmr.2019.01.003","article-title":"Recommandations de bonne pratique pour la prise en charge de la maladie veineuse thromboembolique chez l\u2019adulte. Version courte","volume":"36","author":"Sanchez","year":"2019","journal-title":"Rev Mal Respir"},{"issue":"2","key":"10.1016\/j.revmed.2019.09.003_bib0170","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.revmed.2019.09.003_bib0175","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.revmed.2017.02.006","article-title":"Diagnostic biologique du syndrome des antiphospholipides\u00a0: des crit\u00e8res \u00e0 la pratique","volume":"39","author":"Joste","year":"2018","journal-title":"Rev Med Interne"},{"issue":"Suppl 1","key":"10.1016\/j.revmed.2019.09.003_bib0180","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0049-3848(17)30066-X","article-title":"Antiphospholipid syndrome","volume":"151","author":"Cervera","year":"2017","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.revmed.2019.09.003_bib0185","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/1744666X.2019.1543025","article-title":"Clinical profiles and risk assessment in patients with antiphospholipid antibodies","volume":"15","author":"Kato","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.revmed.2019.09.003_bib0190","doi-asserted-by":"crossref","first-page":"e000785","DOI":"10.1136\/rmdopen-2018-000785","article-title":"Antiphospholipid syndrome: state of the art on clinical practice guidelines","volume":"4","author":"Limper","year":"2018","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.revmed.2019.09.003_bib0195","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.revmed.2019.09.003_bib0200","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1160\/TH04-12-0839","article-title":"Antibody profiles for the diagnosis of antiphospholipid syndrome","volume":"93","author":"Pengo","year":"2005","journal-title":"Thromb Haemost"},{"issue":"17","key":"10.1016\/j.revmed.2019.09.003_bib0205","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A multicenter prospective study","volume":"118","author":"Pengo","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.revmed.2019.09.003_bib0210","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1177\/0961203314545410","article-title":"Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study","volume":"23","author":"Mustonen","year":"2014","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.revmed.2019.09.003_bib0215","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0961203316657433","article-title":"Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity","volume":"26","author":"Yelnik","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2019.09.003_bib0220","first-page":"18","article-title":"Addison's disease in antiphospholipid syndrome: a rare complication","volume":"2018","author":"Oliveira","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"2","key":"10.1016\/j.revmed.2019.09.003_bib0225","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00005792-200303000-00005","article-title":"Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86\u00a0patients","volume":"82","author":"Espinosa","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.revmed.2019.09.003_bib0230","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/jc.2012-4300","article-title":"Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16\u00a0patients","volume":"98","author":"Ramon","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.revmed.2019.09.003_bib0235","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1191\/0961203306lu2318rr","article-title":"Endocrinologic manifestations of the antiphospholipid syndrome","volume":"15","author":"Uthman","year":"2006","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.revmed.2019.09.003_bib0240","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1034\/j.1600-0609.2003.00145.x","article-title":"Antiphospholipid syndrome and endocrine damage: why bilateral adrenal thrombosis?","volume":"71","author":"Berneis","year":"2003","journal-title":"Eur F J Haematol"},{"issue":"6","key":"10.1016\/j.revmed.2019.09.003_bib0245","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2014.01.053","article-title":"14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends","volume":"13","author":"Erkan","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.revmed.2019.09.003_bib0250","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bjh.14632","article-title":"Pathogenesis and management of antiphospholipid syndrome","volume":"178","author":"Arachchillage","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.revmed.2019.09.003_bib0255","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-0036-1597902","article-title":"Direct oral anticoagulants for thromboprophylaxis in patients with antiphospholipid syndrome","volume":"44","author":"Cohen","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.revmed.2019.09.003_bib0260","article-title":"After failure with acenocoumarol, rivaroxaban in antiphospholipid syndrome: A report of 2\u00a0cases","author":"Mateos Rodr\u00edguez","year":"2017","journal-title":"Reumatol Clin"},{"issue":"23","key":"10.1016\/j.revmed.2019.09.003_bib0265","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.2169\/internalmedicine.54.5045","article-title":"Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid","volume":"54","author":"Sugie","year":"2015","journal-title":"Intern Med Tokyo Jpn"},{"issue":"6","key":"10.1016\/j.revmed.2019.09.003_bib0270","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/0961203315624555","article-title":"Direct oral anticoagulants in antiphospholipid syndrome: a real life case series","volume":"25","author":"Betancur","year":"2016","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.revmed.2019.09.003_bib0275","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"issue":"1\u20132","key":"10.1016\/j.revmed.2019.09.003_bib0280","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3121\/cmr.2017.1349","article-title":"Recurrent Thrombosis in Patients with Antiphospholipid Syndrome Receiving Newer Oral Anticoagulants: A Case Report and Review of Literature","volume":"15","author":"Joshi","year":"2017","journal-title":"Clin Med Res"},{"issue":"12","key":"10.1016\/j.revmed.2019.09.003_bib0285","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/0961203317701841","article-title":"Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?","volume":"26","author":"Resseguier","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2019.09.003_bib0290","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2016.12.009","article-title":"The use of direct oral anticoagulants in 56\u00a0patients with antiphospholipid syndrome","volume":"152","author":"Malec","year":"2017","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.revmed.2019.09.003_bib0295","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/MBC.0000000000000541","article-title":"Bilateral adrenal gland hemorrhage in a patient treated with rivaroxaban","volume":"28","author":"Comuth","year":"2017","journal-title":"Blood Coagul Fibrinolysis Int J Haemost Thromb"},{"issue":"12","key":"10.1016\/j.revmed.2019.09.003_bib0300","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-016-0623-7","article-title":"Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin?. A aystematic review of the literature","volume":"18","author":"Dufrost","year":"2016","journal-title":"Curr Rheumatol Rep"},{"issue":"13","key":"10.1016\/j.revmed.2019.09.003_bib0305","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"27","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.revmed.2019.09.003_bib0310","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1076029615615960","article-title":"Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS)","volume":"22","author":"Woller","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"10.1016\/j.revmed.2019.09.003_bib0315","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1076029617729214","article-title":"Protocol modification of apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study","volume":"24","author":"Woller","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"10","key":"10.1016\/j.revmed.2019.09.003_bib0160","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886631930654X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886631930654X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:42:41Z","timestamp":1759336961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S024886631930654X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S024886631930654X"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2019.09.003","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N\u00e9crose h\u00e9morragique bilat\u00e9rale des surr\u00e9nales sous apixaban\u00a0: penser au syndrome des antiphospholipides\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2019.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}